Skip to Content

ARIAD to Present New Preclinical Data on Ponatinib at the American Association for Cancer Research Annual Meeting

Update: Iclusig (ponatinib) Now FDA Approved - December 14, 2012

CAMBRIDGE, Mass.--(BUSINESS WIRE)--Mar 29, 2011 - ARIAD Pharmaceuticals, Inc. (NASDAQ: ARIA) today announced that new preclinical data on ponatinib, the company's investigational multi-targeted tyrosine kinase inhibitor, will be presented at the American Association for Cancer Research (AACR) Annual Meeting to be held April 2-6, 2011 in Orlando, FL.

ARIAD scientist Joseph M. Gozgit, Ph.D., will present the poster entitled, “Ponatinib (AP24534), a potent pan-FGFR inhibitor with activity in multiple FGFR-driven cancer models,” on Tuesday, April 5, 2011 between 8:00 am and 12:00 pm. The ARIAD poster will be presented during the session titled “Experimental and Molecular Therapeutics 25” in Exhibit Hall A4-C, Poster Section 28, Abstract Number 3560.


ARIAD's vision is to transform the lives of cancer patients with breakthrough medicines. The Company's mission is to discover, develop and commercialize small-molecule drugs to treat cancer in patients with the greatest and most urgent unmet medical need - aggressive cancers where current therapies are inadequate. ARIAD's product candidate, ridaforolimus, is an investigational mTOR inhibitor being developed by Merck that has successfully completed a Phase 3 clinical trial in patients with soft-tissue and bone sarcomas and is being studied in multiple cancer indications. ARIAD's second internally discovered product candidate, ponatinib, is an investigational pan-BCR-ABL inhibitor in a pivotal Phase 2 clinical trial in patients with chronic myeloid leukemia and Ph+ acute lymphoblastic leukemia. For additional information, please visit


Contact: ARIAD Pharmaceuticals, Inc.
Maria E. Cantor, 617-621-2208



Posted: March 2011

View comments